New York Life Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

New York Life Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,351	Closed	-$575K	–	1329
2023 Q4	$575K	Sell	18,351 -538	-3%	-$12.8K	0.01%	782
2023 Q3	$394K	Sell	18,889 -3,010	-14%	-$81.8K	﹤0.01%	889
2023 Q2	$524K	Sell	21,899 -2,991	-12%	-$66.5K	0.01%	691
2023 Q1	$468K	Buy	24,890 +1,468	+6%	+$28K	0.01%	1094
2022 Q4	$373K	Buy	23,422 +2,639	+13%	+$41.3K	﹤0.01%	1070
2022 Q3	$340K	Buy	20,783 +1,529	+8%	+$24.8K	﹤0.01%	1047
2022 Q2	$271K	Buy	+19,254	New	+$359K	﹤0.01%	1180

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

New York Life Investment Management's ACAD Position: Q1 2024 in Review

New York Life Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 18,351 shares — an estimated $575K sold.

New York Life Investment Management first reported a position in ACAD in Q2 2022 and held it in 7 quarters. The position peaked at $575K in Q4 2023. 268 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

New York Life Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
New York Life Investment Management sold 18,351 Acadia Pharmaceuticals shares in Q1 2024, an estimated $575K.
New York Life Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2022 and held it in 7 quarters.
New York Life Investment Management's Acadia Pharmaceuticals position peaked at $575K in Q4 2023.
268 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.